Cancer Care · asia
Dual targeting moves into first-line lung cancer treatment: SANOVO prolongs disease control but increases the toxicity burden
For selected patients with both EGFR mutations and MET overexpression, savolitinib combined with osimertinib extended median progression-free survival to 24.9 months. However, grade 3 or higher adverse events increased substantially, and overall survival data remain immature.
Can targeted therapy for lung cancer block another growth pathway that tumors might use before resistance emerges? The phase 3 SANOVO trial brought dual EGFR and MET inhibition into the first-line setting and found significantly longer disease control in patients selected through biomarker screening. The study addresses previously untreated advanced lung cancer, answering a different clinical question from the strategy of adding a MET inhibitor only after progression on treatment.
HUTCHMED announced the results on October 26, and Yi-Long Wu presented the study at the 2026 European Society for Medical Oncology Congress in Madrid. SANOVO enrolled 326 patients across 74 centers in China, all with EGFR mutations and MET overexpression. The randomized, double-blind trial compared savolitinib plus osimertinib with placebo plus osimertinib; crossover was not permitted.
By investigator assessment, median progression-free survival was 24.9 months in the combination group and 13.8 months in the control group, with a hazard ratio for disease progression or death of 0.56 (95% confidence interval, 0.43 to 0.74; P < 0.0001). This endpoint measures the time patients remain alive without disease progression and cannot be interpreted directly as an equivalent extension in lifespan.
The applicability of the efficacy findings depends on how tumors were selected. The trial assessed MET protein expression using immunohistochemistry. Among patients meeting the threshold for high expression, median progression-free survival was 24.8 and 11.1 months in the two groups, with a hazard ratio of 0.45. OncoDaily noted that MET protein overexpression and MET gene amplification are different, and the results cannot be generalized to all patients with EGFR-mutated lung cancer.
Overall survival results offered a preliminary favorable signal: median overall survival was 44.5 months in the combination group and 34.9 months in the control group, with a hazard ratio for death of 0.48. However, both OncLive and OncoDaily noted that survival data were only 40.5% mature, meaning that approximately four in ten participants had died at the time of analysis. Current estimates may still change with further follow-up and should not be regarded as definitive long-term benefits.
Longer disease control also came with a greater treatment burden. Both outlets reported that grade 3 or higher treatment-emergent adverse events occurred in 77.2% of the combination group and 38.4% of the control group; these events were not all necessarily caused by the drugs. OncLive also noted that treatment discontinuation due to adverse events occurred in 14.8% and 4.3%, respectively. Thus, even though the company reported no new safety concerns, the increase in known toxicities remains an important consideration when assessing the value of the two-drug regimen.
### Background
MET signaling can allow tumors to continue transmitting growth signals after EGFR is inhibited. SAFFRON examines the two-drug regimen after progression on osimertinib, while SANOVO moves the intervention to the start of treatment. HUTCHMED plans to submit a supplemental new drug application in China based on these results. Establishing the role of this first-line strategy will also require consideration of testing thresholds, immature survival results, and the higher burden of adverse events.